MAD2 expression in oral squamous cell carcinoma and its relationship to tumor grade and proliferation

Anticancer Research

Volumn 34, Issue 12, 2014, Pages 7021-7027

  Rizzardi, Clara ^a   Torelli, Lucio ^a   Schneider, Manuela ^b   Giudici, Fabiola ^a   Zandona, Lorenzo ^a   Biasotto, Matteo ^a   Di Lenarda, Roberto ^a   Melato, Mauro ^c  

^a UNIVERSITY OF TRIESTE   (Italy)

^b ASS n 2 Isontina   (Italy)

^c INSTITUTE FOR MATERNAL AND CHILD HEALTH IRCCS BURLO GAROFOLO   (Italy)

Author keywords

BUBR1.; MAD2; Oral; Prognostic factor; Spindle checkpoint; Squamous cell carcinoma

Indexed keywords

BUB1 RELATED PROTEIN; DNA; KI 67 ANTIGEN; PROTEIN MAD2; BUB1 PROTEIN, HUMAN; MAD2L1 PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER STAGING; CANCER TISSUE; CARCINOGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; FLOW CYTOMETRY; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LABELING INDEX; LYMPH NODE METASTASIS; M PHASE CELL CYCLE CHECKPOINT; MALE; MOUTH SQUAMOUS CELL CARCINOMA; PATHOPHYSIOLOGY; PLOIDY; PREDICTIVE VALUE; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; RISK FACTOR; TUMOR DIFFERENTIATION; TUMOR GROWTH; BIOSYNTHESIS; CANCER GRADING; CELL PROLIFERATION; CHROMOSOMAL INSTABILITY; DISEASE COURSE; GENETICS; METABOLISM; MIDDLE AGED; MOUTH TUMOR; PATHOLOGY; PROGNOSIS; SQUAMOUS CELL CARCINOMA; TISSUE FIXATION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CELL PROLIFERATION; CHROMOSOMAL INSTABILITY; DISEASE PROGRESSION; FEMALE; HUMANS; LYMPHATIC METASTASIS; M PHASE CELL CYCLE CHECKPOINTS; MAD2 PROTEINS; MALE; MIDDLE AGED; MOUTH NEOPLASMS; NEOPLASM GRADING; PROGNOSIS; PROTEIN-SERINE-THREONINE KINASES; TISSUE FIXATION; TUMOR MARKERS, BIOLOGICAL;

EID: 84918537019     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Bharadwaj R and Yu H: The spindle checkpoint, aneuploidy, and cancer. Oncogene 23: 2016-2027, 2004.
2. Ruddy DA, Gorbatcheva B, Yarbrough G, Schlegel R and Monahan JE: No somatic mutations detected in the Mad2 gene in 658 human tumors. Mutat Res 641: 61-63, 2008.
3. Wu CW, Chi CW and Huang TS: Elevated level of spindle checkprotein MAD2 correlates with cellular mitotic arrest, but not with aneuploidy and clinicopathological characteristics in gastric cancer. World J Gastroenterol 10: 3240-3244, 2004.
4. Wang L, Yin F, Du Y, Du W, Chen B, Zhang Y, Wu K, Ding J, Liu J and Fan D: MAD2 as a key component of mitotic checkpoint. A probable prognostic factor for gastric cancer. Am J Clin Pathol 131: 793-801, 2009.
5. Li GQ and Zhang HF: Mad2 and p53 expression profiles in colorectal cancer and its clinical significance. World J Gastroenterol 9: 1972-1975, 2003.
6. Li GQ and Zhang HF: Mad2 and p27 expression profiles in colorectal cancer and its clinical significance. World J Gastroenterol 10: 3218-3220, 2004.
7. Rimkus C, Friedrichs J, Rosenberg R, Holzmann B, Siewert JR and Janssen KP: Expression of the mitotic checkpoint gene MAD2L2 has prognostic significance in colon cancer. Int J Cancer 120: 207-211, 2006.
8. Pinto M, Vieira J, Ribeiro FR, Soares MJ, Henrique R, Oliveira J, Jerimo C and Teixeira MR: Overexpression of the mitotic checkpoint genes BUB1 and BUBR1 is associated with genomic complexity in clear cell kidney carcinomas. Cell Oncol 30: 389-395, 2008.
9. Choi JW, Kim Y, Lee JH and Kim YS: High expression of spindle assembly checkpoint proteins CDC20 and MAD2 is associated with poor prognosis in urothelial bladder cancer. Virchows Arch 463: 681-687, 2013.
10. Scintu M, Vitale R, Prencipe M, Gallo AP, Bonghi L, Valori VM, Maiello E, Rinaldi M, Signori E, Rabitti C, Carella M, Dallapiccola B, Altomare V, Fazio VM and Parrella P: Genomic instability and increased expression of BUB1B and MAD2L1 genes in ductal breast carcinoma. Cancer Lett 254: 298-307, 2007.
11. Du J, Du Q, Zhang Y, Sajdik C, Ruan Y, Tian XX and Fang WG: Expression of cell-cycle regulatory proteins BUBR1, MAD2, Aurora A, cyclin A and Cyclin E in invasive ductal breast carcinomas. Histol Histopathol 26: 761-768, 2011.
12. Fung MK, Cheung HW, Wong HL, Yuen HF, Ling MT, Chan KW, Wong YC, Cheung AL and Wang X: MAD2 expression and its significance in mitotic checkpoint control in testicular germ cell tumour. Biochim Biophys Acta 1773: 821-832, 2007.
13. Burum-Auensen E, Skotheim RI, Schjberg AR, Rslien J, Lothe RA and Clausen OPF: Spindle proteins are differentially expressed in the various histological subtypes of testicular germ cell tumors. J Carcinog 9: 1, 2010.
14. Wada N, Yoshida A, Miyagi Y, Yamamoto T, Nakayama H, Suganuma N, Matsuzu K, Masudo K, Hirakawa S, Rino Y, Masuda M and Imada T: Overexpression of the mitotic spindle assembly checkpoint genes hBUB1, hBUBR1 and hMAD2 in thyroid carcinomas with aggressive nature. Anticancer Res 28: 139-144, 2008.
15. Tanaka K, Mohri Y, Ohi M, Yokoe T, Koike Y, Morimoto Y, Miki C, Tonouchi H and Kusunoki M: Mitotic checkpoint genes, hsMAD2 and BubR1, in oesophageal squamous cancer cells and their association with 5-fluorouracil and cisplatin-based radiochemotherapy. Clin Oncol 20: 639-646, 2008.
16. Zhang SH, Xu AM, Chen XF, Li DH, Sun MP and Wang YJ: Clinicopathologic significance of mitotic arrest defective protein 2 overexpression in hepatocellular carcinoma. Hum Pathol 39: 1827-1834, 2008.
17. Hisaoka M, Matsuyama A and Hashimoto H: Aberrant MAD2 expression in soft-tissue sarcoma. Pathol Int 58: 329-333, 2008.
18. Yu L, Guo WC, Zhao SH, Tang J and Chen JL: Mitotic arrest defective protein 2 expression abnormality and its clinicopathologic significance in human osteosarcoma. APMIS 118: 222-229, 2010.
19. Ko YH, Roh JH, Son YI, Chung MK, Jang JY, Byun H, Baek CH and Jeong HS: Expression of mitotic checkpoint proteins BUB1B and MAD2L1 in salivary duct carcinomas. J Oral Pathol Med 39: 349-355, 2009.
20. Gladhaug IP, Westgaard A, Schjberg AR, Burum-Auensen E, Pomianowska E and Clausen OPF: Spindle proteins in resected pancreatic head adenocarcinomas: BubR1 is an independent prognostic factor in pancreatobiliary-type tumours. Histopathology 56: 345-355, 2010.
21. Kato T, Daigo Y, Aragaki M, Ishikawa K, Sato M, Kondo S and Kaji M: Overexpression of MAD2 predicts clinical outcome in primary lung cancer patients. Lung Cancer 74: 124-131, 2011.
22. Furlong F, Fitzpatrick P, OToole S, Phelan S, McGrogan B, Maguire A, OGrady A, Gallagher M, Prencipe M, McGoldrick A, McGettigan P, Brennan D, Sheils O, Kay EW, OLeary J and McCann A: Low MAD2 expression levels associate with reduced progression free survival in patients with high-grade serous epithelial ovarian cancer. J Pathol 226: 746-755, 2012.
23. Park PE, Jeong JY, Kim SZ and Park JY: MAD2 expression in ovarian carcinoma: different expression patterns and levels among various types of ovarian carcinoma and its prognostic significance in high-grade serous carcinoma. Korean J Pathol 47: 418-425, 2013.
24. McGrogan B, Phelan S, Fitzpatrick P, Maguire A, Prencipe M, Brennan D, Doyle E, OGrady A, Kay E, Furlong F and McCann A: Spindle assembly checkpoint protein expression correlates with cellular proliferation and shorter time to recurrence in ovarian cancer. Hum Pathol 45: 1509-1519, 2014.
25. Li L, Xu DB, Zhao XL and Hao TY: Combination analysis of Bub1 and Mad2 expression in endometrial cancer: act as a prognostic factor in endometrial cancer. Arch Gynecol Obstet 288: 155-165, 2013.
26. Minhas KM, Singh B, Jiang WW, Sidransky D and Califano JA: Spindle assembly checkpoint defects and chromosomal instability in head and neck squamous cell carcinoma. Int J Cancer 107: 46-52, 2003.
27. Mondal G, Sengupta S, Panda CK, Gollin SM, Saunders WS and Roychoudhury S: Overexpression of Cdc20 leads to impairment of spindle assembly checkpoint and aneuploidization in oral cancer. Carcinogenesis 28: 81-92, 2007.
28. Thirthagiri E, Robinson CM, Huntley S, Davies M, Yap LF, Prime SS and Paterson IC: Spindle assembly checkpoint and centrosome abnormalities in oral cancer. Cancer Lett 258: 276-285, 2007.
29. Moura IM, Delgado ML, Silva PM, Lopes CA, do Amaral JB, Monteiro LS and Bousbaa H: High CDC20 expression is associated with poor prognosis in oral squamous cell carcinoma. J Oral Pathol Med 43: 225-231, 2014.
30. Nakagawa H, Yokozaki H, Oue N, Sugiyama M, Ishikawa T, Tahara E and Yasui W: No mutations of the Bub1 gene in human gastric and oral cancer cell lines. Oncol Rep 9: 1229-1232, 2002.
31. Qi G, Ogawa I, Kudo Y, Miyauchi M, Siriwardena BSMS, Shimamoto F, Tatsuka M and Takata T: Aurora-B expression and its correlation with cell proliferation and metastasis in oral cancer. Virchows Arch 450: 297-302, 2007.
32. Hannisdal K, Burum-Auensen E, Schjberg A, De Angelis PM and Clausen OP: Correlation between reduced expression of the spindle checkpoint protein BubR1 and bad prognosis in tonsillar carcinomas. Head Neck 32: 1354-1362, 2010.
33. Lira RC, Miranda FA, Guimars MC, Sims RT, Donadi EA, Soares CP and Soares EG: BUBR1 expression in benign oral lesions and squamous cell carcinomas: correlation with human papillomavirus. Oncol Rep 23: 1027-1036, 2010.
34. Rizzardi C, Torelli L, Barresi E, Schneider M, Canzonieri V, Biasotto M, Di Lenarda R and Melato M: BUBR1 expression in oral squamous cell carcinoma and its relationship to tumor stage and survival. Head Neck 33: 727-733, 2011.
35. Burum-Auensen E, De Angelis PM, Schjberg AR, Kravik KL, Aure M and Clausen OP: Subcellular localization of the spindle proteins Aurora A, Mad2, and BUBR1 assessed by immunohistochemistry. J Histochem Cytochem 55: 477-486, 2007.
36. Kasai T, Iwanaga Y, Iha H and Jeang KT: Prevalent loss of mitotic spindle checkpoint in adult T-cell leukemia confers resistance to microtubule inhibitors. J Biol Chem 277: 5187-5193, 2002.